HTA72 Examining the Effectiveness of the Cancer Drugs Fund: Are Data Collection Plans Working as Intended?

Abstract

The Cancer Drugs Fund (CDF) in England enables early access to promising new cancer technologies, conditional on additional evidence collection to address any clinical uncertainty. This research reviewed NICE CDF exit evaluations to identify whether the data collection plans were met and whether these sufficiently addressed the uncertainty raised in the original NICE evaluation.